Professor Gareth Jones presented on lifestyle factors and response to anti-TNF treatments in axial spondyloarthritis at one of the world's largest rheumatology conferences.
On Sunday 13th November, ACAMH’s Professor Gareth Jones gave a talk at the American College of Rheumatology’s annual scientific meeting (ACR Convergence 2022), in Philadelphia, USA. He presented data on the influence of lifestyle factors on TNF inhibitor treatment response, in axial spondyloarthritis, on the outcome of response to TNF inhibition treatment.
The research behind this presentation consisted of an analysis of data from 14 countries within the EuroSpA collaboration. EuroSpA is a research collaboration consisting of 17 countries across Europe, who collect data on patients with axial spondyloarthritis.
Using BASDAI-50 as the primary outcome, the analysis - of nearly 17,000 people - found that patients who were overweight or obese were less likely to respond to the treatment (53% and 44% achieved BASDAI-50 response, respectively) compared to 60% of those with normal BMI. Smokers were also slightly significantly, less likely to respond (50%) compared to non-smokers (54%).
The ACR Convergence 2022 ran from 11th-15th November 2022. You can view a copy of the poster from this presentation here.